A Phase 1 Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer


Abstract

In the completed Phase 1 open-label dose-escalation portion of this study in patients (pts) with advanced solid tumors, the single-agent MTD was declared to be 60 mg BID
Poster
non-peer-reviewed

A Phase 1 Study of MEK Inhibitor MEK162 (ARRY-438162) in Patients with Biliary Tract Cancer


Author Information


PDF Share